The Life Raft Group
  • Facebook
  • Instagram
  • Linkedin
  • Pinterest
  • Twitter
  • YouTube
Get Support Today - 973-837-9092
  • About Us
    • What We Do
      • Budget and Philosophy
      • Research Philosophy
    • Our Team
      • Job Opportunities
    • Our Members
      • Member Stories
      • In Memoriam
    • Board of Directors
    • Contact Us
  • About GIST
    • GIST Diagnosis
    • GIST FAQ’s
    • Types of GIST
    • GIST Survival Statistics
    • Risk of Recurrence
    • Resistant GIST
  • Manage GIST
    • Treatments for GIST
      • Surgery
      • Preventative Gleevec
      • Gleevec
      • Sutent
      • Stivarga
      • Generics
    • GIST Clinical Trials
    • Monitoring CTs, PET Scans and MRIs
    • GIST Mutations and Mutation Testing
    • Coping With GIST
    • Managing Side Effects
    • Proper Nutrition for GIST Cancer Patients
  • GIST Research
    • Columbia Collaborative Research Project
    • Pathway To A Cure
    • GIST Patient Registry
    • LRG Research Team
    • GIST Tissue Bank
  • Get Support
    • Virtual GIST Tumor Board
    • GIST Specialists Database
    • Join Our Community
    • Find A Support Group
    • Financial Aid
    • Important Links
  • Get Involved
    • Events
      • Life Fest 2018
    • Join The LRG Community
    • Update Medical Records
    • Join our Tissue Bank
    • Volunteer
    • Advocacy
    • Awareness
  • Library
    • Newsroom
    • Newsletter Archive
    • In Memoriam
    • Photos
    • Videos
    • Webcasts
    • Site Map
  • Donate
    • Ways to Fundraise
    • Planned Giving
Search the site...

The LRG Research Team

GIST Research Team Dr. Sebastian BauerDr. Sebastian Bauer – West German Cancer Center, University of Essen, Germany

Sebastian Bauer, M.D. graduated from the University of Wuerzburg Medical School, Germany and received his medical oncology training at the West German Cancer Center in Essen, Germany. He completed a postdoctoral fellowship at Jonathan Fletcher’s research lab (Brigham & Women’s Hospital in Boston, MA), and now works as a medical oncologist (sarcoma program) and scientist at the West German Cancer Center in Essen. His research in GIST has focused on evaluation and validation of therapeutically relevant signaling pathways in GIST.

 

GIST Research Team Dr. Christopher CorlessDr. Christopher Corless – Oregon Health & Science University

After undergraduate studies at the University of California, Berkeley, Dr. Christopher Corless received his M.D. and Ph.D. degrees from Washington University, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women’s Hospital, Boston, where he also completed fellowship training in GI Pathology and GU Pathology. In 1994, he joined the faculty of Oregon Health & Science University, as an Assistant Professor. He has served as the residency program director in Pathology and is currently medical director of surgical pathology for OHSU Hospital. He is also director of the Cancer Pathology Shared Resource for the Oregon Cancer Institute. In addition to practicing surgical pathology, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors. An author on over 125 publications, he was promoted to Professor of Pathology in 2004. Dr. Corless is lending his expertise as leader of the Primary Resistance Project.

Dr. Maria Debiec-Rychter – Catholic University of Leuven. Belgium

Dr. Maria Debiec‐Rychter obtained an M.D. degree (1978) and Ph.D. degree in Somatic Genetics (1986) from the Medical University of Lodz, Poland. She remained at the University of Lodz as an Associate Professor until 1989, when she became a visiting scientist to the Michigan Cancer Foundation, Detroit, MI. Dr. Debiec‐Rychter has worked with Wayne State University, Detroit, MI and the Armed Forces Institute of Pathology, Washington, DC. She has been appointed as an Associate Professor at Catholic University of Leuven, Belgium since 1999. Her research interests are related to the cytogenetic and molecular characterization of solid tumors, and cancer-related targeted therapy. Currently, she is involved in the studies of the molecular mechanisms of resistance to imatinib in GIST patients. Dr. Debiec‐Rychter is leading the Stable Disease Project.

Dr. Anette Duensing – University of Pittsburgh Cancer Center

Dr. Anette Duensing studied medicine in Germany and the U.K., and received her M.D. from the University of Hannover Medical School, Germany. She wrote her dissertation on molecular genetics of liver tumors in the Department of Pathology at the University of Hannover Medical School. Dr. Duensing then completed three years of residency training in this department, where she participated mainly in the morphological and molecular diagnosis of hematological diseases. In 1999, Dr. Duensing joined Dr. Jonathan Fletcher’s laboratory at the Brigham and Women’s Hospital in Boston for a post‐doctoral fellowship. In the past few years, she has been leading the GIST‐related studies in Dr. Fletcher’s lab. During that time, most of her research was focused on activated intracellular signaling pathways in GISTs that are triggered by the mutant KIT protein. This research has led to the identification of proteins which might be targeted by new kinase inhibitors as a complement to KIT inhibition. Since 2003, Dr. Duensing is Research Assistant Professor in the Department of Pathology at the University of Pittsburgh Medical School.

Dr. Jonathan Fletcher – Brigham and Women’s Hospital

Dr. Jonathan Fletcher is a medical and pediatric oncologist whose clinical activities are in cancer diagnostics with a focus on molecular and cytogenetic methods. His laboratory program is studying tyrosine kinase (such as KIT and PDGFRA) mechanisms in sarcomas. He has developed novel methods for rapid profiling of tyrosine kinase activation in frozen human tumors, and these techniques have identified effective therapeutic targets in several types of sarcomas, including GIST. His primary research aims are to identify therapeutic strategies that can synergize with KIT inhibition to cure GIST. Dr. Fletcher is head of the Life Raft Group’s Research Team as well as leading the KIT Degradation and Resource Development Projects.

 

Dr. Michael Heinrich – Oregon Health & Science University

Dr. Michael Heinrich is currently a Professor of Medicine at Oregon Health & Science University. He earned his medical degree in 1984 from Johns Hopkins School of Medicine in Baltimore and completed both his residency training and Hematology and Medical Oncology fellowship at OHSU. His primary research interest is in the development of novel tyrosine kinase inhibitors for treatment of human cancers. Dr. Heinrich’s research includes both pre‐clinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. Dr. Heinrich is leading the KIT Degradation Project.

 

Dr. Matthew van de Rijn – Stanford University Medical Center

Matt van de Rijn received his M.D. and Ph.D. degrees from the University of Amsterdam in 1986. Subsequently, he performed a postdoctoral fellowship in the laboratory of Dr. Irving Weissman, which was followed by residency training in surgical pathology at Stanford University Medical Center. He next worked as an assistant professor in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania Medical Center in Philadelphia. In 1998, he returned to Stanford and is now an associate professor of pathology. Upon his return to Stanford, he started collaborating with the combined laboratories of Drs. Pat Brown and David Botstein and developed an interest in gene microarray analysis as used for gene expression profiling and comparative genomic hybridization. These techniques, combined with the technique of tissue microarrays in which gene array data can be validated by immunohistochemistry and in situ hybridization studies, now form the core of his laboratory. In his laboratory, his work is mainly focused on sarcomas with specific emphasis on leiomyosarcomas and gastrointestinal stromal tumors. His research is translational in nature and is focused on the discovery of new diagnostic markers, the discovery of new tumor subsets with different prognoses and/or different response to various treatments and the identification of new therapeutic targets. Dr. van de Rijn is hosting the Adult Tissue Bank.

 

Dr. Brian Rubin – The Cleveland Clinic

Dr. Brian Rubin graduated from University of California, Berkeley with a B.A. in Cell Biology in 1983. He spent the next 3 years in the Peace Corps working for the WHO Malaria Control Program in Thailand. He moved on to work as a research technician at Amgen from 1986‐1987. He attended the M.D./Ph.D. program at Cornell University Medical College from 1987‐1995. Dr. Rubin was a resident and fellow at Brigham and Women’s Hospital from 1995‐2000 where he did focused fellowships in soft tissue pathology with Dr. Chris Fletcher and a post‐doc in the lab of Dr. Jonathan Fletcher working on genomics of sarcomas including GIST. In 2000, he moved to the University of Washington where he spent 5 1/2 years as the Director of Bone and Soft Tissue Pathology. Dr. Rubin is now the director of Soft Tissue Pathology at Cleveland Clinic. He currently shares appointments at Cleveland Clinic in the Department of Molecular Genetics at the Lerner Research Institute and in the Department of Pathology. Dr. Rubin’s lab is focused on genomics and proteomics of sarcomas, targeted therapies of sarcomas and developing mouse models of sarcomas.

Dr. Tamas Ordog, Adjunct Researcher, The Mayo Clinic

Dr. Tamas Ordog graduated from the University of Pécs Medical School, and has done Postdoctoral Research at the University of Pécs and University of Texas Medical School at Houston. At the Mayo Clinic his research focuses around the molecular, cellular and translational biology of the gastrointestinal neuromuscular system, with particular focus on interstitial cells of Cajal (ICC). He is also involved in isolated ICC precursors and animal models of diabetes, eating disorders, aging and gastrointestinal stromal tumors we study the mechanisms-of-action of drug candidates that could be developed into novel therapies for restoring normal ICC networks and making neoplastic ICC more sensitive to targeted cancer therapy.

LRG Events

<< Apr 2018 >>
MTWTFSS
26 27 28 29 30 31 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 1 2 3 4 5 6

Website Navigation

  • Life Fest 2018
  • How to be a Patient-Powered H.E.R.O.*
  • GIST Awareness
  • About Our Organization
  • Understanding GIST
  • Donate
  • Subscribe to the LRG Newsletter
  • GIST FAQ’s
  • Managing GIST
  • GIST Research
  • Get Support
  • Medical Update Form
  • Patient Registry Info & Consent Form
  • GIST Patient Registry
  • Join Our Tissue Bank
  • Library

Recent Posts

  • GIST Updates: SPAEN and ESMO 2018 Meetings

  • Deciphera Logo

    Deciphera Pharmaceuticals Announces the Start of Phase 3 Clinical Trial with DCC-2618 in GIST

  • 15 Years, 15 wishes

    15 years-15 wishes for 2018 from the Life Raft Group

Stay Connected

Follow @Liferaftgroup

The Life Raft Group

is a 501 (c)(3) non-profit organization
(tax id: 82-0547746) providing support through information, education, and innovative research to patients with a rare cancer called GIST (Gastrointestinal Stromal Tumor). View our By-Laws here and our 990 Form here


The LRG website is dedicated in perpetuity to the memory of Mary S. Golnik.

HONcode

This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information:
verify here.


Silver GuideStar - Seal of Transparency
Foundation Alliance Member Badge

The information provided on the LRG site is designed to support, not to replace, the relationship that exists between a patient/site visitor and his/her physician. Read our Privacy Policy

The Life Raft Group
155 US Highway 46, Suite 202
Wayne, NJ 07470 USA

Phone 973-837-9092

© 2018 The Life Raft Group. All rights reserved. | About | Donate | Site Map